Genetika+ employs a proprietary platform that integrates stem cell technology, genomics, and artificial intelligence (AI) to revolutionize the treatment of psychiatric and neurological disorders. The process begins with the collection of a patient's blood sample, which is then reprogrammed into induced pluripotent stem cells (iPSCs) using Nobel Prize-winning techniques. These iPSCs are differentiated into specific neuronal subtypes relevant to the patient's condition, such as neurons from the frontal cortex for major depression. This innovative approach allows for the generation of patient-derived neurons, which are subsequently analyzed using advanced computer vision and deep learning algorithms to assess their functionality and response to various compounds.

The technology further enhances precision medicine by utilizing a comprehensive biobank that encompasses extensive clinical, imaging, and genomic data from a diverse patient population. By combining morphological, molecular, and clinical data, Genetika+ creates a validated "multifeature brain signature" that predicts drug response for individual patients. This enables healthcare providers to gain deep insights into the mechanisms of action of different compounds, facilitating personalized treatment strategies and improving outcomes for patients suffering from a range of CNS disorders, including major depression, anxiety, schizophrenia, and Alzheimer's disease.

Israel

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Genetika+

Company Details